Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 22, 2026
TickeronGET DAILY SIGNALS
Dermata Therapeutics (DRMA): Exploring the +400% Upside to the $4 Analyst Target

Dermata Therapeutics (DRMA): Exploring the +400% Upside to the $4 Analyst Target

Key Takeaways

  • The $4 reference target is the one current, publicly discussed analyst price objective (Maxim Group, Buy), not an average of many analyst targets.
  • At a recent price near $0.78, reaching $4 would require upside of roughly 400%, an exceptionally large move for any stock.
  • DRMA is Dermata Therapeutics, a pre-revenue skincare company that pivoted in late 2025 from prescription acne drug development to OTC/DTC products under its "Tome" brand.
  • The strongest support is positive Phase 3 acne data validating its Spongilla "Bioneedle" technology and a lower-cost, faster OTC route to market.
  • The biggest risks are no revenue, a going-concern warning, recurring dilution, and a single raw-material supplier based in Russia.
  • Readers can track Major News, Today's Price Move, the Forecast, and Earnings on dedicated pages for more detail.
  • Explore Trending AI Robots for AI-driven tools that monitor stocks and ETFs in real time.

Understanding the $4 Analyst Target

Because DRMA lacks the multiple credible current targets needed to build a meaningful average, the $4 objective used here comes from identifiable public discussion rather than a calculated consensus. The single active analyst target is Maxim Group's $4.00, maintained by analyst Anthony Vendetti with a Buy rating in August 2026. Maxim had cut the target to $4 from $10 in April 2026, citing share dilution and a wider fourth-quarter GAAP loss per share. This illustrates a core point: the target reflects a post-reverse-split, pre-revenue company whose valuation is highly sensitive to capital raises. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Where DRMA Stands Today and the Road Ahead

Dermata shares have recently traded around $0.78, giving the company a market capitalization of only about $5 million. Reaching $4 would require a gain of roughly 400%, a very large move by any standard. The stock completed a 1-for-10 reverse split in August 2025 and has since traded in a wide range, remaining near the lower end of its 52-week span. With no product revenue and limited institutional ownership, the path to $4 would almost certainly depend on successful commercialization of the Tome skincare line, a credible revenue trajectory, and additional capital raised on less dilutive terms — a combination the company has not yet demonstrated.

Bullish Factors That Could Drive the Stock Higher

The bull case rests on validated science and a faster market route. Dermata's lead candidate, XYNGARI, met its primary endpoint in the Phase 3 STAR-1 trial for moderate-to-severe acne in early 2025, supporting the mechanism of its Spongilla lacustris-derived "Bioneedle" technology. Management's September 2025 pivot to over-the-counter (OTC) and direct-to-consumer (DTC) skincare avoids the multi-year, costly FDA new drug approval process, targeting the roughly 50 million U.S. acne patients with a potentially premium product. Cost discipline is evident: operating expenses fell about 38% in 2025, and the company held cash and equivalents of $4.4 million at mid-2026 with plans for a product launch in August 2026.

Key Risks to Consider

The risks are substantial and largely structural. Dermata has generated no revenue and posted a 2025 net loss of $7.56 million, with an accumulated deficit near $78 million. Its auditor has included a going-concern warning, and management expects to need additional financing — a recurring source of dilution that directly erodes per-share value. The company relies on a single supplier, Reka-Farm LLC in Russia, for its core sponge ingredient, exposing it to geopolitical and supply-chain disruption. Regulatory uncertainty remains: if regulators classify the Bioneedle as an active ingredient rather than an inactive one, an OTC monograph path could be blocked. A terminated licensing agreement with Villani Inc. adds litigation risk, while an unproven consumer brand must compete against large, well-funded skincare incumbents.

Technical Picture and Market Dynamics

The long-term trend remains negative. Following the 1-for-10 reverse split, shares have continued to trade below their 200-day moving average, a durable sign of persistent downtrend, even as shorter-term moving averages have at times turned constructive. With a 52-week range spanning roughly $0.95 to $5.98 and a market cap near $5 million, liquidity is thin, meaning any move — up or down — can be amplified. Psychological whole-dollar levels such as $1 and $2 would be notable milestones, but the stock currently sits far below them. From what I see, monitoring these levels closely helps put potential moves in context.

What to Watch Going Forward

Analyst price targets are typically set on a roughly 12-month research horizon, though Maxim's target predates the company's commercial launch and may not reflect a specific timing assumption. The items that matter most are the success of the August 2026 Tome product launch, the first signs of actual revenue, quarterly cash burn and any capital raises, the resolution of the Villani licensing dispute, and FDA positioning around the OTC monograph. Because Dermata's runway extends only into late 2026 or early 2027, financing news will likely move the shares as much as, or more than, operating results. I’m watching this closely as developments unfold.

AI Daily Buy/Sell Signals

AI Daily Buy/Sell Signals uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a thinly traded micro-cap like Dermata, where sentiment can turn quickly, these signals can help traders discover opportunities, monitor existing positions, and spot changing trends more efficiently than manual screening. Traders interested in a data-driven complement to fundamental research may find the tool a useful way to stay ahead of fast-moving price action. In my view, this has become a regular part of how I review positions like this one.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: DRMA

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Momentum Indicator for DRMA turns negative, indicating new downward trend

DRMA saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 98 similar instances where the indicator turned negative. In 91 of the 98 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for DRMA turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 57 similar instances when the indicator turned negative. In 53 of the 57 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DRMA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for DRMA entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where DRMA advanced for three days, in 148 of 189 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

DRMA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.085) is normal, around the industry mean (3.596). P/E Ratio (-0.182) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).

The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. DRMA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DRMA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -12%. For the same Industry, the average monthly price growth was -18%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 105%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 37%. For the same stocks of the Industry, the average monthly volume growth was 41% and the average quarterly volume growth was -9%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 70
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
3525 Del Mar Heights Road
Phone
+1 858 800-2543
Employees
9
Web
https://www.dermatarx.com
Interact to see
Advertisement
SSO is a 2x daily leveraged ETF (exchange-traded fund) that seeks double the daily return of the S&P 500, while XXX is a non-leveraged, passive fund blending roughly 75% S&P 500 exposure with 25% XRP, a major cryptocurrency. Both funds charge comparable fees — about 0.87% for SSO and roughly 0.85% for XXX — but their risk profiles are fundamentally different.
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.